NRx starts commercial manufacturing of preservative-free ketamine ahead of FDA approval in 2026

NRx Pharmaceuticals has begun commercial manufacturing of its preservative-free ketamine product in the US, anticipating FDA approval in summer 2026. This ketamine formulation avoids toxic preservatives and uses a high-throughput blow-fill-seal process, addressing ongoing supply shortages in the US market. The initial production capacity supports significant sales growth and can be scaled as demand increases. NRx is also building its commercial team to support market launch and aims to provide a reliable domestic ketamine supply for treating depression and related conditions.